Хирургическая профилактика генетически обусловленных форм рака молочной железы у женщин
Диссертация
Хирургическое лечение в группе 1 выполнено 55(96,5%) пациентам. 2 пациентам группы 1 с диагнозом первично-множественный синхронный рак хирургическое лечение не проводилось в связи с генерализацией процесса. В зависимости от возраста, стадии заболевания и сопутствующей патологии, объем оперативного лечения был различен: в 11 (20%) случаях — радикальная резекция молочной железы с регионарной… Читать ещё >
Список литературы
- Аничков НМ., Кветной И. М., Коновалов С. С. Биология опухолевого роста. СПб.: Издательство «Прайм Еврознак». — 2004.
- Берштейн Л.М. Гормональный канцерогенез. Наука, Спб., 2000. -С. 199
- Вторушен С.В. Особенности экспрессии рецепторов половых гормонов при инфильтрирующем протоковом раке молочной железы: Дисс. на соиск. уч. степени к.м.н. Томск 2006.
- Ганцев Ш. X., Ханов А. М., Демидов С. М. и др. Рак молочной железы. -М.: ООО Медицинское информационное агентство, 2004. -С. 116.
- Гарькавцева Р.Ф., Гарькавцев И. В. Молекулярно-генетические аспекты злокачественных новообразований. // Вестник РАМН. -1999. № 2. — С. 38−44.
- Гарькавцева Р.Ф., Казубская Т. П. и др. Наследственный рак: идентификация, генетическая гетерогенность, медико-генетическое консультирование // Вестник РАМН. 2001. — № 9. — С. 32.
- Гольдберг Е.Д., Дыгай A.M. Удут В. В. и др. Закономерности структурной организации систем жизнеобеспечения в норме и при развитии патологического процесса. Томск, 1996. — С.34−36.
- Грудинина Н.А., Голубков В. И., Тихомирова О. С., Брежнева Т. В. и др. Преобладание широко распространенных мутаций в гене ВКСА1 у больных семейными формами рака молочной железы Санкт-Петербурга // Ж. Генетика. Том 41.- ЗГ 23: 2005.
- Давыдов М.И., Аксель Е. М. // Вестник РОНЦ им Н.Н. Блохина. -Т. 17. -№ 3 (прил.1). 2006.
- Залетаев Д. В., Горбунова В. Н., Бабенко О. В. Онкогеномика и молекулярная диагностика в онкологии. Москва. — 2001.
- Иванова В.И., Киселев Л. Л. Геномика в медицине. М. ИКЦ. -«Академкнига»: 2005.
- Иващенко Ю.Д., Быкорез А. И. Полипептидные факторы роста и канцерогенез.- Киев. 1990. — С.65.
- Ковынцев Н.Н. Аугментационная маммопластика силиконовыми протезами. Москва. — 2000.
- Логинова А. Н. Молекулярно-генетический анализ наследственной формы рака молочной жёлезы и/или яичников: Автореф. дисс. на соискание уч. степени к.м.н. Москва. — 2004.
- Любченко Л.Н., Гарькавцева Р. Ф. Клинико-генетическая гетерогенность семейного рака молочной железы // Современная Онкология. Том б, 32. — 2004.
- Любченко Л.Н., Поспехова Н. И., Портной К. И. и др. Наследственные формы рака молочной железы и/или яичников: прогноз, тактика лечения и профилактика // Материалы VII Российской Онкологической конференции. Москва. — 2003.
- Мандельштам М. Ю. Молекулярно-генетический анализ моногенных форм атеросклероза и рака молочной железы у жителей Санкт-Петербурга: Автореф. дисс. на соискание уч. степени д.б.н. -Санкт-Петербург. 2005.
- Albano W, Recabaren J, Lynch H et al. Natural history of hereditary cancer of the breast and colon // Cancer 1982. Vol. 50, pp. 360−363.
- Anglian Breast Cancer Study Group / Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases //Br. J. Cancer, 83. 2000, pp. 10 301−10 308.
- Antoniou A. C., Pharoah P. D., McMullan G., Day, N. E., Ponder B. A., and Easton D. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study // Genet. Epidemiol. 2001. — Vol. 21, pp. 1−18.
- Antoniou A. C., Pharoah P. D., McMullan G., Day N. E., Stratton M. R., Peto J., Ponder B. J., and Easton D. F. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes // Br. J. Cancer. 2002. — Vol. 86, pp. 76−83.
- Arkwright, P. D., Laurie, S., Super, M., Pravica, V., Schwarz, M. J., Webb, A. K., and Hutchinson, I. V. TGF-beta (l) genotype and accelerated decline in lung function of patients with cystic fibrosis //Thorax. -2000. -Vol. 55, pp. 459162.
- Bader K., Pellettiere E., Curtin J. W. Definitive surgical therapy for the «premalignant» or equivocal breast lesion // Plast. Reconstr. Surg. -1970. Vol. 46, p. 120.
- Bartek J., Falck J., Lukas J. Chek2 kinase-a busy messenger // Nature Rev. Mol. Cell. Biol. 2001. — Vol 2. pp.877−886.
- Bartlett W. An anatomic substitute for the female breast // Ann Surg. -1917.-Vol. 66, pp.208−211.
- Barton F., English J.M., Kingsley W., Fietz M. Glandular excision in a total glandular mastectomy and modified radical mastectomy: a compari-sion // Plast. Reconstr. Surg. 1991. — Vol. 88, No. 3, pp. 389−392.
- Bartsch D., Hahn S. A., Danichevski K. D., Ramaswamy A., Bastian D., Galehdari H., Barth P., Schmiegel W., Simon В., and Rothmund M. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. // Oncogene. 1999. — Vol.8, pp. 2367−2371.
- Bascom C.C., Sipes N.J., Coffey R.J., Moses H.L. Regulation of epithelial cell proliferation by transforming growth factors. // J. Cell Biochem.- 1989. Vol. 39, № 1, pp. 25−32.
- Bensimon R.H., Bergmeyer J.M. Improved aesthetics in breast reconstruction: Modified mastectomy incision and immediate autologous tissue reconstruction // Ann. Plast. Surg. 1995. — Vol 34, p.229
- Bierie В., Moses H.L. Tumor microenvironment: TGF?: the molecular Jekyll and Hyde of cancer // Nat. Rev. Cancer. 2006. — Vol. 6, pp. 506 520.
- Blobe G.C., Schiemann WP, Lodish HF. Mechanisms of disease: role of transforming growth factor (b) in human disease // N. Engl. J. Med. -2000. Vol 342, pp. 1350 — 1358.
- Boardmann L. A., Thibodeau S. N., Schaid D. J. et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome // Ann Intern. Med.- 1998. Voll28, pp. 896−899.
- Brandon M., Baldi P., Wallace D.C. Mitochondrial mutations in cancer / Nature Publ. Group. 2006. — pp. 1−16.
- Breslow N. E, Day N.E. Statistical methods in cancer research. Vol. 1: The analysis of case-control studies. IARC Scientific Pub. 1980. — No. 32. Lyon: IARC.
- Cauch F.J., et al., BRCA 1 mutation in women attending clinics that evaluate the risk of breast cancer // N Engl. J. Med. 1997. — Vol. 336. -pp. 1409−1415.
- Chang-Claude J., Eby N., Kiechle M., Bastert G., and Becher H. Breastfeeding and breast cancer risk by age 50 among women in Germany.- Cancer Causes Control. 2000. — Vol. 11. — pp. 687−695.
- Chen Т., Carter D., Garrigue-Antar L., and Reiss M. Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res. — 1998. — Vol58. — pp. 4805−4810.
- Chinnery P. F., Samuels D. C., Elson J., Turnbull D. M. The epidemiology of pathogenic mitochondrial DNA mutations // Lancet. -2002. Vol. 360.-pp. 1323−1325.
- Chun H. H., Gatti R. A. Ataxia-telangiectasia, an evolving phenotype. DNA repair. 2004. — 3: pp. 1187−1196.
- Cox A., Dunning A. M., Garcia-Closas M. et al. A common coding variant in CASP8 is associated with breast cancer risk // Nat. Genet. 2007. № 1, p. 7.
- Crilly A., Hamilton J., Clark C. J., Jardine A., and Madhok R. Analysis of transforming growth factor betal gene polymorphisms in patients with systemic sclerosis / Ann. Rheum. Dis. 2002. — Vol. 61. — pp. 678 681.
- Cuzick J., Baum M. Tamoxifen and collateral breast cancer // Lancet. -1985. № 2, p.282.
- Day N. Oakes S., Luben R., Khaw К. Т., Bingham S., Welch A., and Wareham N. EPIC-Norfolk: study design and characteristics of the cohort / European Prospective Investigation of Cancer // Br. J. Cancer. 1999. -Vol. 80 (Suppl. 1), pp. 95−103.
- Derynck R. SMAD proteins and mammalian anatomy // Nature 393. -1998.-pp. 737−739.
- Derynck R., Akhurst R. J., and Balmain A. TGF-beta signaling in tumor suppression and cancer progression // Nat. Genet. 2001. — Vol. 29. -pp. 117−129.
- Digweed M., Sperling K. Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks / DNA Repair. 2004. — Vol. 3, pp. 1207−1214.
- Dinner M.I., Sampliner J., Artz J.S., et al. Optimal cosmetic autogenous reconstruction with modified radical mastectomy // Surg. Gynecol. -Obstet. 1993. Vol. 83, pp. 176.
- Dufault M. R., Betz В., Wappenschmidt B. et al. Limited relevance of the CHEK2 gene in hereditary breast cancer / Int. J. Cancer. 2004. — Vol. 10, pp. 320−325.
- Dumont N, Arteaga C.L. Transforming growth factor-b and breast cancer. Tumor promoting effect of transforming growth factor-b. Breast Cancer Res. 2000. — Vol. 2, pp. 125 — 132.
- Dunning A. M., Dowsett M., Healey C.S. et al. Polymorphisms associated with circulating sex homone levels in postmenopausal women // J. Natl. Cancer. Inst. 2004. — Vol. 96, pp. 936−945.
- Dunning A.M., Ellis P.D., McBride S., et al. A transforming growth factor bl signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer / Cancer Res. -2003.-Vol. 63, p. 2610. p
- Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials // Lancet. 1998. -Vol. 351, pp. 1451—67.
- Easton D. F., Peto J., and Babiker A. G. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group / Stat. Med. 1991.- Vol. 10, pp. 1025−1035.
- Elliott L.F., Eskenazi L., Beagle P.H., Jr. et al. Immediate TRAM flap breast reconstruction: 128 consecutive cases // Plast. Reconstr. Surg. -1993.-Vol. 92, p. 217.
- Eng C., de la Chapelle A. Genetic testing for cancer predisposition // Ann. Rew. Med. 2001. — Vol. 51, pp. 420−423.
- Feigelson H. S., McKean-Cowdin R., Coetzee G. A. et al. Building a Multigenic Model of Breast Cancer Susceptibility: CYP17 and HSD17B1 Are Two Important Candidates / Cancer Research. 2001. — Vol. 61, pp. 785−789.
- Fisher В., Constantino J.P., Wickerham D. L. et al. Tamoxifen for prevention of breast cancer. Report of the National Surgical Adjuvant Breast and Bowel Project P-l stady // J. Natl. Cancer Inst. 1998. — 90, pp. 1371−1388.
- Ford D, Easton D, Bishop D et al. Consortium BCL. Risk of cancer in BRCA 1 mutation carriers // Lancet. — 1994. Vol. 343, pp. 692−5.
- Ford D., Easton D., Stratton M. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families / Am. J. Hum. Genet. 1998. — Vol. 62, pp. 676−689.
- Freeman B. S. Subcutaneous mastectomy for benign breast lesions with immediate or delayed prosthetic replacement // Plast. Reconstr. Surg. 1962. Vol. 30, p.676.
- Gail M.N., Constantino J.P., Bryant J., et al. Weighing the risk and benefits of tamoxifen treatment for preventing breast cancer // J Natl Cancer Inst. 1999. — Vol. 91, pp. 1829—46.
- Garcfa-Closas M. et al. Large-scale evolution of candidate genes association between VEGF polimorphism and bladder cancer risk // Plos. Genet. 2007. — Vol. 3, pp. 287−293
- Gatti R. A., Berkel I., Boder E. et al. Localization of an ataxia telangiectasia gene to chromosome 1 lq 22−23 // Nature. 1988. — Vol. 336, pp. 577−580.
- Gayther S. Frequently occurring germ line mutations of BRCA 1 gene // Am J Hum Genet. 1997. — Vol. 60, pp. 1013−20.
- Gobbi H., Arteaga C.L., Jensen R.A., et al. Loss of expression of transforming growth factor b type II receptor correlates with high tumor grade in human breast in-situ and invasive carcinomas // Histopathology. -2000.-Vol. 36, pp. 178−80.
- Goldman L.D., Goldwyn R.M. Some anatomical consideration of subcutaneous mastectomy // Plast. Reconstr. Surg. 1973. — Vol. 51, p.501.
- Gorski В., Debniak Т., Ma’sojc B. et al. Germline 657del5 mutation in the NBS1 gene in breast cancer patients / BCLC Familial Cancer 2003. -Vol. 2, pp. 214−5.
- Gorski В., Debniak Т., Masojc B. et al. Germline 657del5 mutation in the NBS1 gene in breast cancer patients / Int. J. Cancer. 2003. — Vol. 106, pp. 379−381.
- Goumans M. J., Valdimarsdottir G., Itoh S., Rosendahl A., Sideras P., and ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors // EMBO J. 2002. — Vol. 21, pp. 17 431 753.
- Grainger D J., Heathcote K., Chiano M., et al. Genetic control of the circulating concentration of transforming growth factor type 1 // Hum Mol Genet. 1999. — Vol. 8, pp. 93 — 97.
- Grainger D. J., Snieder H., Kemp P. R., Metcalfe J. C., Carter N. D., and Spector T. D. Genetic control of the circulating concentration of transforming growth factor type betal. Hum. Mol. Genet. 2001. — Vol. 5, pp. 67−73.
- Guillemette C., Millikan R.C., Newman B. et al. Genetic Polymorphisms in UGT1A1 and Association with Breast Cancer among African Americans // Cancer Research. -2000. Vol. 60, pp. 950−956.
- Hartman L.C., Crotty T.P., Myers J.L., Arnold P.G., Frost M.H., Jenkins R.B. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer // N. Engl. J. Med. 2001. — Vol. 245 (3), pp. 61−75.
- Harvey J. A. and Bovbjerg’V. E. Quantitative assessment of mammography breast cancer risk // Radiology. 2004. — Vol. 230, pp. 29−41.
- Heldin C.H., Miyazono K. & Dijke P.ten TGF-b signaling from cell membrane to nucleus through SMAD proteins // Nature. -1997. Vol. 390, pp. 465−471.
- Hishida A., Iwata H., Hamajima N., et al. Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women // Breast Cancer. 2003. — Vol. 10, pp. 63 — 9.
- Holweg С. Т., Baan С. C., Niesters H. G., Vantrimpont P. J., Mulder P. G., Maat, A. P., Weimar, W., and Balk, A. H. TGF-betal gene polymorphisms in patients with end-stage heart failure // J. Heart Lung Transplant. 2001. — Vol. 20, pp. 979−984.
- Hoogerbrugge N., Bult P., Widt-Levert L.M. et al. High Prevalence of Premalignant Lesions in Prophylactically Removed Breasts From Women at Hereditary Risk for Breast Cancer // J. Clin. Oncol. 2003. — Vol. 21, pp.41 -45.
- Horton С. E., Carraway J. H. Total Mastectomy with Immediate Reconstruction for Premalignant Disease: In R. M. Goldwyn (Ed.), Plastic and Reconstructive Surgery of the Breast. Boston: Little, Brown. — 1976. — pp. 459−464.
- Huang X. E., Hamajima N., Katsuda N. et al. Association of p53 co-don Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphism with the risk of Japanese breast cancer // Breast Cancer. 2003. — Vol. 103, pp. 431−433.
- Hung R.J. et al. GST, NAT, SULT1A1, CYP1B1 genetic polimor-phisms, interactions with environmental exposures and bladder cancer in high-risk population // Int. J Cancer. 2004. — Vol. 110, pp. 598−604
- Ishibe N., Hankilson S. E.,'Colditz G. A. et al. Cigarette smoking, cytochrome P450 1 Al polymorphisms, and breast cancer risk in the Nurses' Health Study / Cancer Res. 1998. — Vol. 58, pp. 667−671.
- Jen-Jan Pan et. Al. Increased expration of TGF-bl reduced tumor growth of human U-87 Glioblastoma Cell in vivo // Cancer Immunology, Immunotherapy и Biotechnology Letters. 2007.
- Kaklamani V.G., Hou N., Bian Y., et al: TGFBR1*6A and Cancer Risk: A Meta-Analysis of Seven Case-Control Studies // J. Clin. Oncol. -2003. Vol. 21, pp. 3236−3243.
- Kleeff J., Ishiwata Т., Maruyama H., Friess H., Truong P., Buchler M. W., Falb D., and Korc M. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer // Oncogene. 1999. — Vol 18, pp. 5363−5372.
- Kolonel L.N., Henderson B.E., Hankin J.H., et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics // Am. J. Epidemiol. 2000. — Vol. 151, pp. 346 — 57.
- Kopp A., Jonat W., Schmahl M., Knabbe C. Transforming growth factor. 2 levels in plasma of patients with metastatic breast cancer treated with tamoxifen / Cancer Res. -4995. Vol. 55, pp. 4512−4515.
- Kretzschmar M. / Transforming growth factor-b and breast cancer. -Transforming growth factor-b/SMAD signaling effects and cancer / Breast Cancer Res. 2000. — Vol. 2, pp. 107 — 15.
- Kroll S.S., Ames F., Singletary S.E. et al: The oncology risks of skin preservation at mastectomy when combined with immediate reconstruction of the breast // Surg Gynecol Obstet. 1991. — Vol. 172, pp. 17−20.
- Lacbani S., Sloane J., Gusterson B. et al. A detailed analysis of morphological features associated with breast cancer in patients harboring mutations in BRCA1 and BRCA2 predisposition genes // J Natl Cancer Inst.1999.-Vol. 90, pp. 1138−45.
- Lacha J., Hubacek J. A., Potmesil P., Viklicky O., Malek I., and Vitko S. TGF-beta 1 gene polymorphism in heart transplant recipients-effect on renal function // Ann. Transplant. -2001. Vol. 6, pp. 39−43.
- Lee L.G., Connell C.R., Bloch W. Allelic discrimination by nicktran-slation PCR with fluorogenic probes / Nucleic Acids Res. 1993. — Vol. 21, pp. 3761 -3766.
- Liaw D., Marsh D., Li J. et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome // Nat Genet. 1997. — Vol. 16: 64, pp. 310−9.
- Lohmueller K.E., Pearce C.L., Pike M., et al: Meta-analysis of genetic studies supports a contribution of common variants to susceptibility со common disease // Nat. Genet. -2003. Vol. 33, pp. 177−182.
- Lucke C.D., Philpott A., Metcalfe J.C., et al. Inhibiting mutations in the transforming growth factor b type 2 receptor in recurrent human breast cancer / Cancer Res. 2001. — Vol. 6, pp. 1482 — 5.
- Lyons R.M., Moses H.L. Transforming growth factors and the regulation of cell proliferation. // Eur.J. Biochem. 1990. — Vol. 187, N 3, pp. 467−473.
- Macleod K. Tumor supressor genes // Curr. Opin. Genet. Develop. -2000. Vol. 10, pp. 81−93.
- Maliniac J. W. Use of pedicle dermo-fat flap in mammaplasty // Plast. Reconstr. Surg. 1953. — Vol. 12, p. 110.
- Malkin D, Li F, Strong L et al. Germ-line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms // Science. -1990.-Vol. 250, p. 1233.
- Malkin D., Li F.P., Strong L.C. et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms // Science. 1990. — Vol. 250, pp. 1235−1238.
- Marcus J., Watson P., Page D. et al. Heredity breast cancerpathobiol-ogy, prognosis, and BRCA1 and BRCA2 gene linkage // Cancer. 1996. -Vol. 77, pp. 679−709.
- Markowitz S. TGF-beta receptors and DNA repair genes, coupled targets in a pathway of human colon carcinogenesis // Biochim. Biophys. Acta. 2000. — Vol.1470, M13-M20.
- Massague J., Blain S.W., Lo R.S. TGFb signaling in growth control, cancer, and heritable disorders // Cell. 2000, Oct 13. -Vol. 103(2), pp. 295 — 297.
- Massague J. How cells read TGF Signals // Nature Rev. Mol. Cell Biol.-2000.- № 1, pp. 169−178.
- Massague J., Blain S.W., Lo R.S. TGFb signaling in growth control, cancer, and heritable disorders // Cell. 2000. — Vol. 103, pp. 298−309.
- McDonnell S.K., Schaid D. J., Myers J.L. et al. Efficacy of Contralateral Prophylactic Mastectomy in Women with a Personal and Family History of Breast Cancer // J. Clin. Oncol. 2001. — Vol. 19, pp. 3938−3943.
- Meijers-Heijboer H., Van den O.A., Klijn J. et al. Low-penetrance susceptibility to breast cancer due to HEK2(*)1 lOOdelC in noncarriers of BRCAlor BRCA2 mutations // Nat. Genet. 2002. — Vol. 31, pp. 55−59.
- Miki Y., Swensen J., Shattuck-Eidens D. et al. A strong Candidate for the breast and ovarian cancer susceptibility gene BRCA1 // Science. -1994.- Vol. 266, p. 66.
- Miki Y., Swensen J., Shattuck-Eidens D. et al. A Strong Candidate for the breast and ovarian cancer susceptibility gene BRCA 1 // Nat. Med. -2001.-Vol. 7, pp. 552−6.
- Mitchell G., Antoniou A.C., Warren R. et al. Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers // Cancer Res. 2006. — Vol. 66, pp. 1866−1872.
- Nandi S., Guzman R. C., Yang J. Hormones and mammary carcinogenesis in mice, rats, and humans: A unifying hypothesis // Proc. Natl. Acad. Sci. 1995. — Vol. 92, pp. 3650−3657.
- Nelen M. R., Padberg G. W., Peeters E. A. et al. Localization of the gene for Cowden disease to chromosome 10q22−23 // Nat. Genet. 1996. -Vol. 13, pp. 114−116.
- Nelson H.D., Humphrey L.L., Nygren P., et al: Postmenopausal Hormone Replacement Therapy: Scientific Review // JAMA. 2002. — Vol. 288, pp. 872−881.
- Newman B, Austin M, King M. Inheritance of human breast cancer. Evidance for autosomal dominant transmission in high-risk families // Proc Nat Acad Sci USA. 1988. — Vol. 85, pp. 3044−8.
- Oft M., Akhurst, R. J., and Balmain, A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels // Nat. Cell Biol. 2002. -Vol 4, pp. 487−494.
- Pasche В., Kaklamani V.G., Hou N., et al: TGFBR1 *6A and Cancer: A Meta-Analysis of 12 Case-Control Studies // J Clin Oncol. 2004. -Vol. 22, pp. 756−758.
- Pasche В., Kolachana P., Nafa K., et al: T beta R-I (6A) is a candidate tumor susceptibility allele / Cancer Res. 1999. — Vol. 59, pp. 5678−5682.
- Pasche В., Kaklamani V., Hou N., and Rademaker A. Association Between TGFBR1 *6A and Cancer: Cancer Genetics Program. -Division of Hematology/Oncology. Department of Medicine, Department of Preventive Medicine. — 2001.
- Pennisi V. R., Capozzi A. The incidence of obscure carcinoma in subcutaneous mastectomy: Results of a national survey // Plast. Reconstr. Surg. 1975. — Vol. 56, p. 9.
- Pennisi V. R. Subcutaneous mastectomy and fibrocystic disease of the breast // Clin. Plast. Surg. 1976. — Vol. 3, p. 205.
- Pennisi V. R., Capozzi A. Subcutaneous mastectomy: An interim report on 1244 patients // Ann. Plast. Surg. 1984. — Vol. 12, p. 340.
- Petit J.Y., Greco M. on behalf of EUSCOMA Position Paper. Quality control in prophylactic mastectomy for women at risk of breast cancer // European J. Cancer. -2002. Vol. 38, p. 23−26.
- Pharoah P. D., Antoniou A., Bobrow M. et al. Polygenic susceptibility to breast cancer and implications for prevention // Nat. Genet. 2002. -Vol. 31, pp. 33−36.
- Pharoah P. D., Day N. E., Duffy S., Easton D. F., and Ponder, B. A. Family history and the risk of breast cancer: a systematic review and metaanalysis // Int. J. Cancer. 1997. — Vol. 71, pp. 800−809.
- Pietenpol J.A., Holt J.T., Stein R.W., Moses H.L. TGFbl suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. // Proc. Natl. Acad. Sci. USA. 1990. — Vol. 87, № 12, pp. 37 583 762.
- Pim D., Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression // Int. J. Cancer. 2004. — Vol. 108, pp. 196−199.
- Position Paper / Quality control in prophylactic mastectomy for women at risk of breast cancer // European J. Cancer. 2002, 38, pp. 23−26.
- Powels T.J., Jones A.L., Ashley S.A., et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial / Breast Cancer Res. Treat. -1994.-Vol. 31, pp. 73—82.
- Powels T.J., Hardy J.R., Ashley S.A., et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer // Br J Cancer. 1989. — Vol. 60, pp. 126—33.
- Powels T.J., Eeles R., Ashley S.A., et al. Interim analysis of the incidence of breast cancer in Royal Marsden Hospital tamoxifen randomized chemopreventional trial // Lancet. 1998. — Vol. 362, pp. 98—101.
- Pulleyn, L. J., Newton, R., Adcock, I. M., and Barnes, P. J. TGFbetal allele association with asthma severity // Hum. Genet. 2001. Vol. 109, pp. 623−627.
- Randall P., Dabb R., Loc N. «Apple coring» the nipple in subcutaneous mastectomy // Plast. Reconstr. Surg. 1979. — Vol. 64, p. 800.
- Rebbeck T.R., Friebel Т., Lynch H. T. et al. Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1and BRCA2 Mutation Carriers: The PROSE Study Group // J. Clin. Oncol. 2004. — Vol. 5, pp. 1055−1062.
- Renwick A., Thompson D., Seal S. et al. ATM mutations that cause ataxia telangiectasia are breast cancer susceptibility alleles // Nat. Genet. -2006. Vol. 38, pp. 873−875.
- Rice C.O., Strickler J. H. Adenomammectomy for benign breast lesions // Surg. Gynecol. Obstet. 1951. — Vol. 93, p. 759.
- Roberts A.B., Wakefield LM. The two faces of transforming growth factor b in carcinogenesis // Proc. Natl. Acad. Sci. USA. -2003. Vol. 100, pp. 8621 -3.
- Robson M. et al. Outcome of Preventive Srgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers // J. Clin. Oncol. -2002. Vol. 5, pp. 1260−1268.
- Rosfjord E. C., and Dickson R. B. Growth factors, apoptosis, and sur-• vival of mammary epithelial cells // J. Mammary Gland-Biol. Neoplasia.1999.-Vol. 4, pp. 229−237.
- Sato Т., Akiyama F., Sakamoto G. et al. Accumulation of genetic alterations and progression of primary breast cancer / Cancer Res. 1991. -Vol. 51, pp. 5794−57.
- Sato Т., Akiyama F., Sakwnoto G. et. al. Accumulation of genetic alterations and progression of primary breast cancer // Cancer Res. 1992. -Vol. 51, pp. 5−94
- Savitsky K., Bar-Shira A., Gilad S. et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase // Science. 1995. — Vol. 268, pp. 1749−1753.
- Scheuer L., Kauff N., Robson M. et al Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers // J. Clin. Oncol. 2002. — Voi:5, pp. 1260−1268.
- Schnitt S., Goldwyn R., Slavin S. Mammary ducts in the areola: Implications for patients undergoing recontructive surgery of the breast // Plast. Reconstr. Surg. 1993. — Vol. 92, p. 1290.
- Schulze A., Lehmann K., Jefferies H. В., McMahon M., and Downward J. Analysis of the transcriptional program induced by Raf in epithelial cells // Genes Dev. -2001. Vol. 15, pp. 981−994.
- Seal S., Barfoot R., Jayatilake H., et al. Evaluation of Fanconi Anemia in familial breast cancer // BCLC Familial cancer. 2003. — Vol. 2, pp. 212−3.
- Shatalova E. G., Walter S. E., Favorova О. O. et al. Genetic polymorphisms in human SULT1 Al and UGT1 Al genes associate with breast tumor characteristics: a case-series study // Breast Cancer Research. 2005. -Vol. 7, pp. 909−921.
- Siegel P.M., Shu W., Cardiff R.D., Muller W.J., Massague J. Transforming growth factor b signaling impairs Neu-induced mammary tumori-genesis while promoting pulmonary metastasis. / Cancer Res. 2001. -Vol. 58, pp. 6259−6265.
- Smith P., McGuffog L., Easton D.F. et al. A genome wide linkage search for breast cancer susceptibility genes // Genes Chromosomes Cancer. 2006. — Vol. 45, pp. 646−655.
- Steffen J., Varon R., Mosor M. et al. Increased cancer risk of hetero-zygotes with NBS1 germline mutations in Poland // Int. J. Cancer. 2004. -Vol. Ill, pp. 67−71.
- Stone J., Dite G. S., Gunasekara A. et al. The heritability of mammo-graphically dense and nondense breast tissue. Cancer Epidemiol. / Bio-markers Prev. 2006. — Vol. 15, pp. 612−617.
- Stoppa-Lyonnet D., Ansquer Y., Dreyfus H. et al. Familial Invasive Breast Cancers: Worse Outcome Related to BRCA1 Mutations // J. Clin. Oncol. 2000. — Vol. 18, pp. 4053−4059.
- Stoppa-Lyonnet D., Hall J., Janin N. et al. Low-penetrance genes: he-terozygote ATM mutation carriers and breast cancer risk // BCLC Familial Cancer. 2003. — Vol. 2, pp. 185−6.
- Sugiura, Y., Niimi, Т., Sato, S., Yoshinouchi, Т., Banno, S., Naniwa, Т., Maeda, H., Shimizu, S., and Ueda, R. Transforming growth factor be-tal gene polymorphism in rheumatoid arthritis // Ann. Rheum. Dis. 2002. -Vol. 61, pp. 826−828.
- Swift M., Morrell D., Cromartie E. et al. The incidence and gene frequency of ataxia-telangiectasia in the United States // Ami. J. Hum. Genet. 1986. — Vol. 39, pp. 573−583.
- Szabo C., King M.C. Population genetics of BRCA 1 and BRCA 2 // Am J Hum Genet. 1997. — Vol. 60, pp. 1013−20.
- Taylor A. M., Byrd P. J. Molecular pathology of ataxia telangiectasia // J. Clin. Pathol. 2005. — Vol. 58, pp. 1009−1015.
- The Breast Cancer Association Consortium. Commonly studied SNPs and breast cancer: negative results from 12,000 32,000 cases and controls from the Breast Cancer Association Consortium // J. Natl. Cancer Inst. -2006. Vol. 98, pp. 1382−1396.
- Thompson P. A., Shields P. G., Freudenheim J. L., Stone A., Vena J. E., Marshall J. R. et al. Genetic polymorphisms in catechol О methyltrans-ferase, menopausal status and breast cancer risk / Cancer Res. 1998. -Vol. 58, pp. 2107−2110.
- Thompson P. A., Ambrosone C. Molecular Epidemiology of Genetic Polymorphisms in Estrogen Metabolizing Enzymes in Human Breast Cancer // Journal of the National Cancer Institute Monographs. 2000. — Vol. 27, pp. 125−134.
- Thorek M. / Plastic Surgery of the Breast and Abdominal Wall. -1942. Springfield. — 111.: Charles C. Thomas.
- Toth B.A., Glafkides M.C. Immediate breast reconstruction with dee-pithelialized TRAM flaps: Techniques for improving breast reconstruction // Plast. Reconstr. Surg. 1990. — Vol. 85, p. 967.
- Venkitaraman A. Breast cancer genes and DNA repair // Science. -1999. Vol. 286, pp. 1100−02.
- Verhood L.C., Brekelmans C.T., Seynaeve C. et al. Survival in Hereditary Breast Cancer Associated With Germline Mutations of BRCA2 // J Clin Oncol. 1999. — Vol. 17, pp. 3396−3402.
- Veronesi U., Maisonneuve P., Costa A., et al. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomised women // Lancet. 1998. — Vol. 362, pp. 937.
- Wakefield, L. M., Yang, Y. A., and Dukhanina, O. Transforming growth factor-beta and breast cancer: lessons learned from genetically altered mouse models / Breast Cancer Res. 2000. — Vol. 2, pp. 100−106.
- Walsh V., Casadei S., Coats K.H. et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2 and TP53 in families at high risk of breast cancer // JAMA. 2006. — Vol. 295, pp. 1379−1388.
- Wang Q., Zhang H., Fishel R., Greene M.I. BRCA1 and cell signaling // Oncogene. 2000. — Vol. 19, pp. 6152−6158.
- Warthin A. Heredity with reference to carcinoma as shown by the study of caces exemined in pathological laboratory of the University of Mechigan 1895−1913 // Arch. Int. Med. 1913. — Vol. 12, pp. 546−555.
- Welsh P.A., King M.-C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer // Hum. Mol.Genet. 2001. — Vol. 10, pp. 705 713.
- Williams W., Anderson D. Genetic epidemiology of breast cancer analysis of 200 Danish pedigrees / Genet Epidem. 1984. — Vol. 1, pp. 720.
- Wjittemore A., Gong G., Itnyre J. Prevalence and contribution of BRCA1 mutation in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer // Am. J. Hum. Genet. 1997. — Vol. 60, pp. 496−504.
- Woods J. E. Subcutaneous mastectomy: Current state of the art // Ann. Plast. Surg. 1983.-Vol. 11, p. 541.
- Wooster R., Bignell G., Lancaster J. et al. Identification of the breast cancer susceptibility gene BRCA 2 //Nature. 1995. — Vol. 378, pp. 78 992.
- Yamada Y. Association of a Leu (10)-Pro polymorphism of the transforming growth factor-betal with genetic susceptibility to osteoporosis and spinal osteoarthritis / Mech. Ageing Dev. 2000. — Vol. 116, pp. 113−123.
- Zheng W., Xie D., Cerhan J.R., Sellers T.A., Wen W., Folsom A.R. Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done intake, and breast cancer risk // Cancer Epidemiol. Biomarkers Prev. -2001.-Vol. 10, pp. 89−94.